脉冲释放PLGA微球单次注射疫苗的免疫原性研究
研究开发模拟多剂次疫苗方案的脉冲释放PLGA微球,体外筛选16种含牛血清白蛋白的微球制剂,选出3种脉冲释放制剂在小鼠中评估免疫原性;低剂量微球诱导的抗BSA IgG峰值滴度为13.9±1.3和13.7±2.2 log2,与三次bolus注射的15.5±1.5 log2统计学相似;高剂量微球为16.1±2.1 log2,对照为17.7±2.2 log2。
要点
- 16种PLGA微球制剂体外筛选释放动力学,3种脉冲释放制剂用于小鼠免疫原性研究。
- 低剂量微球诱导抗BSA IgG峰值滴度13.9±1.3和13.7±2.2 log2,与bolus对照15.5±1.5 log2统计学相似。
- 高剂量微球诱导峰值滴度16.1±2.1 log2,对照为17.7±2.2 log2,所有微球制剂与bolus对照统计学相似。
核心结论
- 聚合微球脉冲释放抗原是单次注射疫苗的有前景方法,可能减轻发展中国家免疫接种的后勤负担。
研究设计与样本
- 体外筛选16种含牛血清白蛋白(BSA)作为模型疫苗抗原的聚乳酸-羟基乙酸共聚物(PLGA)微球制剂释放动力学,选出3种具理想脉冲释放特征的制剂在小鼠中研究免疫原性。
主要发现
- 两种低剂量微球制剂诱导的抗BSA IgG抗体峰值滴度为13.9±1.3和13.7±2.2 log2,而0、4、8周三次bolus注射等效累积剂量对照为15.5±1.5 log2。
- 高剂量微球制剂诱导的峰值抗体滴度为16.1±2.1 log2,对照为17.7±2.2 log2。
- 所有三种体内研究的微球制剂诱导的峰值抗体滴度与bolus对照统计学相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The World Health Organization's Expanded Programme on Immunization has led to a dramatic rise in worldwide vaccination rates over the past 40years, yet 19.4 million infants remain underimmunized each year. Many of these infants have received at least one vaccine dose but may remain unprotected because they did not receive subsequent booster doses due to logistical challenges. This study aimed to develop injectable controlled release microparticles with kinetics that mimic common vaccine dosing regimens consisting of large antigen doses administered periodically over the course of months in order to eliminate the need for boosters. Sixteen poly(lactic-co-glycolic acid) (PLGA) microsphere formulations containing bovine serum albumin (BSA) as a model vaccine antigen were screened in vitro to determine their respective release kinetics. Three formulations that exhibited desirable pulsatile release profiles were then selected for studying immunogenicity in mice. Two low-dose microsphere formulations induced peak anti-BSA IgG antibody titers of 13.9±1.3 and 13.7±2.2 log2 compared to 15.5±1.5 log2 for a series of three bolus injections delivered at 0, 4, and 8weeks with an equivalent cumulative dose. Similarly, high-dose formulations induced peak antibody titers that were 16.1±2.1 log2 compared to 17.7±2.2 log2 for controls. All three microparticle formulations studied in vivo induced peak antibody titers that were statistically similar to bolus controls. These results suggest that pulsatile antigen release from polymeric microparticles is a promising approach for single-injection vaccination, which could potentially reduce the logistical burden associated with immunization in the developing world.
引用
- Guarecuco R, Lu J, McHugh KJ, et al. Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination. Vaccine. 2017. PMID: 28625520. doi:10.1016/j.vaccine.2017.05.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。